LHF-535 by Kineta for Arenaviridae Infections: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LHF-535 overview

LHF-535 is under development for the treatment of arenaviridae infection and lassa fever. The drug candidate is a suspension which is administered orally and intravenously. It is developed based on the AViiD screening platform.

Kineta overview

Kineta formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of treatments for neurodegenerative diseases. The company uses its drug discovery platform for the development of its pipeline products. Kineta‘s pipeline product candidates include YTX-7739 for the treatment of Parkinson’s disease; YTX-9184 for the treatment of dementia with lewy bodies. Other pipeline also comprises of additional programs with undisclosed product candidates that are focused on frontotemporal lobar dementia (FTLD), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Kineta is headquartered in Boston, Massachusetts, the US.

For a complete picture of LHF-535’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.